Ischemia-Modified Albumin Levels in Patients With Essential Thrombocytosis

Year 2018, Volume: 10 Issue: 3, 341 - 346, 23.10.2018

Ercan Ersoy Utku Erdem Soyaltın , Ahmet Peker , Ayfer Çolak , Cengiz Ceylan , Harun Akar

https://doi.org/10.18521/ktd.376723

Abstract

Objective: The aim of this study was to investigate the levels of ischemia-modified albumin (IMA) in people with essential thrombocytosis (ET).

Methods: A total of 30 patients with ET patient group and 30 volunteers with no known disease control group (C group) were included in this study after the approval of ethics committee and written informed consent was obtained. Patients with a history of major thrombosis were excluded. IMA levels and independent variables were investigated and effects on thrombosis susceptibility were also studied. In addition to that; comorbid disease state, drug use and used drugs group were questioned in patient group and effects of them on IMA levels were studied.

Results: In our study, when ET patient group and C group were compared, the mean serum IMA levels in ET patient group and C group was detected as 0,6726 (0,527-0,776) Absorbans Unite (ABSU) and 0,4342 (0,346-0,612) ABSU respectively and in ET patient group was significantly higher than C group (p<0,001). The glucose, total cholesterol and triglyceride values were significantly higher in ET patient group (p= 0,026, p= 0,058, p= 0,004, respectively). There is a correlation between IMA concentration and age (p= 0,042).

Conclusions: In our study IMA levels were found significantly high in ET patient group, this supports increased risk of thrombosis in ET. The difference of metabolic parameters between the ET patient group and C group can be explained by insulin resistance and atherosclerosis background caused by chronic inflammation.

Keywords

Ischemia Modified Albumin, Essential Thrombocytosis, Thrombosis

Esansiyel Trombositozlu Hastalarda İskemi-Modifiye Albumin Düzeyleri

Abstract

Keywords

İskemi Modifiye Albumin, Tromboz, Esansiyel Trombositoz

References

• Dahabreh IJ, Zoi K, Giannouli S, et al. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2009; 33(1): 67-73.
• Patriarca A, Pompetti F, Malizia R, et al. Is the absence of JAK2 V617F mutation a risk faktor for bleeding in essential thrombocythemia? An analysis of 106 patients. Blood Transfus. 2010; 8(1): 21-7.
• Çetin G. Esansiyel trombositemi. İ.Ü. Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri Sempozyum Dizisi 2005; 277-83.
• Palandri F, Ottaviani E, Salmi F, et al. JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. Leuk Lymphoma 2009; 50(2): 247-53.
• Tefferi A. Diagnosis and clinical manifestations of essential thrombocytemia. www.uptodate.com (This topic last updated: March 15, 2015).
• Tefferi A. Essential Thrombocythemia and thrombocytosis. John P. Greer, John Foerster, George M. Rodgers, Frixos Paraskevas, Bertil Glader, Daniel A. Arber, Robert T. Means Jr. Wintrobes Clinical Hematology. 12th ed. Lippincott, Williams&Wilkins, 2009;1352-60.
• Gangat N, Wolanskyj AP, McClure RF, et al.Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single instutional study of 605 patients. Leukemia 2007;21:270-6.
• Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-24.
• Özdem S, Çete Y, Dönmez L, et al. Sağlıklı Yetişkinlerde ve Akut Koroner Sendromlu Hastalarda Serum İskemi Modifiye Albumin (İMA) Düzeyleri. Türkiye Acil Tıp Dergisi, 2005; 5: 169-174.
• Karahan SC. İskemi Modifiye Albümin ve Klinik Önemi. Türk Biyokimya Dergisi 2009; 34:45-6.
• Turedi S, Patan T, Gündüz A, et al. Ischemia-modified albumin in the diagnosis of pulmonary embolism: an experimental study. Am J Emerg Med. 2009; 27: 635-40.
• Ma SG, Jin Y, Hu W. Et al. Evaluation of ischemia-modified albumin and C-reactive protein in type 2 diabetics with and without ketosis. Biomark Insights 2012; 7: 19-26.
• Bar-Or D, Curtis G, Rao N. et al. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem. 2001; 268: 42-7.
• Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocytemia. A study of 605 patients. Haematologica 2008:93;1645-51.
• Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocytemia beyond the first decade: Life expectancy, long term complication rates, and prognosis factors. Mayo Clin Proc. 2006:81;159-66.
• Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med 2011;49(2):177-84.
• Kato M, Hisatome I,TomikuraY, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol. 2005;96(11): 1576-8.
• Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004; 25(1):4-7.
• Landolfi R, Di Gennaro L. Pathophysiology of thrombosis in myeloproliferative neoplasms. Haematologica 2011;96(2):183-6.
• Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia andpolycythemiavera:different role of C-reactive protein and pentraxin 3. Haematologica 2011; 96(2):315-8.
• Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? Arterioscler Thromb Vasc Biol. 2005;25(4): 658-70.
• Barbui T, Carobbio A, Rambaldi A, et al. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 2009;114(4):759-63.
• CarobbioA, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117(22):5857-9.